Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early
January 28, 2016 6:59 AM ESTOpdivo Study Demonstrates Superior Overall Survival Compared to Therapy of Investigators Choice in Patients with Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that a randomized Phase 3 study evaluating Opdivo (nivolumab) versus investigators choice in patients with... More
